From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) is amino acids 24 to 41 fragment of IGF-I. IGF-I, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I is partly responsible for systemic growth hormone (GH) activities. IGF-I has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) regulates somatic growth and behavioral development .
BMS-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC50s of 100 nM and 73 nM, respectively. BMS-536924 has anti-cancer activity .
IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions) .
IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) TFA is amino acids 24 to 41 fragment of IGF-I. IGF-I TFA, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I TFA is partly responsible for systemic growth hormone (GH) activities. IGF-I TFA has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) TFA regulates somatic growth and behavioral development .
Leucinostatin A (Antibiotic P168) is a nonapeptide exerting a remarkable activity especially against Candida albicans and Cryptococcus neoformans. Leucinostatin A is a hydrophobic nonapeptide antibiotic. Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells. Antiprotozoal activies .
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .
Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis.
S961 is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively .
S961 acetate is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively .
Picropodophyllin-d6 (AXL1717-d6) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies .
S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively .
Robatumumab (Sch 717454) is an anti-human IGF-1R(insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research .
D-chiro-Inositol is an epimer of myo-inositol found in certain mammalian glycosylphosphatidylinositol protein anchors and inositol phosphoglycans possessing insulin-like bioactivity. D-chiro-Inositol is used clinically for the treatment of polycystic ovary syndrome (PCOS) and diabetes mellitus, which can reduce hyperglycemia and ameliorate insulin resistance .
IGF-1R inhibitor-2 (example 121) is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor. Downregulation of IGF-1R can reverse the transformed phenotype of tumor cells and potentially render them susceptible to apoptosis .
NVP-AEW541 (AEW541 ) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 has antitumor activity .
NVP-AEW541 dihydrochloride (AEW541 dihydrochloride) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 dihydrochloride also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 dihydrochloride has antitumor activity .
AVJ16 is a cancer cell migration inhibitor that targets the insulin-like growth factor 2 mRNA binding protein IGF2BP1 to inhibit the migration of H1299 cells with high endogenous IGF2BP1 expression. AVJ16 interferes with IGF2BP1 binding target mRNA to regulate gene expression and translation .
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). NBI-31772 hydrate is also a nonpeptide ligand that releases bioactive IGF-I from the IGF-I/IGFBP-3 complex (Kis=1-24 nM for all six human subtypes). Anxiolytic and antidepressant-like effects .
GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC50s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC50>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity .
I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R (insulin-like growth factor-1 receptor tyrosine kinase). I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and is preferentially cytotoxic to nutrient-deprived PANC1 cells. I-OMe-Tyrphostin AG 538 is an ATP-competitive inhibitor of phosphatidylinositol-5-phosphate 4-kinase α (PI5P4Kα), with an IC50 of 1 µM .
ML-290 is a first-in-class and potent relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC50 of 94 nM . ML290 is a biased allosteric agonist at the relaxin receptor RXFP1.
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM .
BML-280 (VU0285655-1) is a potent and selective phospholipase D2 (PLD2) inhibitor. BML-280 has the ability to prevent caspase-3 cleavage and reduction in cell viability induced by high glucose. BML-280 can be used for rheumatoid arthritis research .
Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.
Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.
MCE offers a unique collection of 1816 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.
IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) is amino acids 24 to 41 fragment of IGF-I. IGF-I, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I is partly responsible for systemic growth hormone (GH) activities. IGF-I has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) regulates somatic growth and behavioral development .
IGF-I (30-41) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions) .
IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions) .
IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) TFA is amino acids 24 to 41 fragment of IGF-I. IGF-I TFA, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I TFA is partly responsible for systemic growth hormone (GH) activities. IGF-I TFA has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) TFA regulates somatic growth and behavioral development .
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .
S961 is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively .
S961 acetate is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively .
Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies .
S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively .
Human Growth Hormone (1-43) is an N-terminal fragment of human growth hormone with specific and pronounced insulin-like activity. Human Growth Hormone (1-43) can be used to study the function and metabolic pathways of growth hormone, a potential obesity-related factor .
Gly-Pro-Glu is a neuroactive peptide with a potent action on acetylcholine release. Gly-Pro-Glu is the N-terminal tripeptide of insulin-like growth factor-I. Gly-Pro-Glu inhibits glutamate binds to N-methyl-D-aspartate (NMDA) receptor with an IC50 value of 14.7 μM. Gly-Pro-Glu can be used for the research of neuroprotection .
Robatumumab (Sch 717454) is an anti-human IGF-1R(insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research .
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM .
Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis.
D-chiro-Inositol is an epimer of myo-inositol found in certain mammalian glycosylphosphatidylinositol protein anchors and inositol phosphoglycans possessing insulin-like bioactivity. D-chiro-Inositol is used clinically for the treatment of polycystic ovary syndrome (PCOS) and diabetes mellitus, which can reduce hyperglycemia and ameliorate insulin resistance .
Leucinostatin A (Antibiotic P168) is a nonapeptide exerting a remarkable activity especially against Candida albicans and Cryptococcus neoformans. Leucinostatin A is a hydrophobic nonapeptide antibiotic. Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells. Antiprotozoal activies .
The INSL4 protein plays a potentially critical role in the regulation of trophoblast development and bone formation. The specific mechanism of trophoblast development deserves further study. INSL4 Protein, Human (HEK293, His) is the recombinant human-derived INSL4 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of INSL4 Protein, Human (HEK293, His) is 114 a.a., with molecular weight of ~9.0 kDa.
IGF-I protein is similar to insulin and exerts effective growth-promoting activity as a ligand of IGF1R. Binding to the α subunit of IGF1R activates intrinsic tyrosine kinase, triggering autophosphorylation of the β subunit. IGF-I Protein, Salmon is the recombinant IGF-I protein, expressed by E. coli , with tag free. The total length of IGF-I Protein, Salmon is 70 a.a., with molecular weight of ~8 kDa.
The IGF2 protein is an important member of the insulin-like growth factor family and plays an important role in mammalian growth, fetoplacental development, and adult glucose metabolism. Regulated by placental prolactin, affecting tissue differentiation. IGF2 Protein, Human (GST) is the recombinant human-derived IGF2 protein, expressed by E. coli , with N-GST labeled tag. The total length of IGF2 Protein, Human (GST) is 151 a.a., with molecular weight of 44.1 kDa.
IGF-I/IGF-1 Protein, Mouse (His) is a mitogenic cytokine, binds to IGF type 1 receptor, and modulates growth in many tissues, such as nervous tissue, lymphoid tissue, reproductive tissue, smooth muscle, endothelium, and bone. IGF1 also mediates neuroprotective mechanism.
The IGF-I/IGF-1 protein is structurally similar to insulin and has potent growth-promoting activity. As a physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts, exceeding the efficacy of insulin at lower concentrations. IGF-I/IGF-1 Protein, Mouse (N-His) is the recombinant mouse-derived IGF-I/IGF-1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of IGF-I/IGF-1 Protein, Mouse (N-His) is 70 a.a., with molecular weight of ~10 kDa.
The INSL6 protein plays a crucial role in sperm development and fertilization, highlighting its importance in male reproductive biology. Its potential function in promoting sperm development and successful fertilization emphasizes its importance in reproductive physiology. INSL6 Protein, Human (HEK293, His) is the recombinant human-derived INSL6 protein, expressed by HEK293 , with C-His labeled tag. The total length of INSL6 Protein, Human (HEK293, His) is 178 a.a., with molecular weight of ~22.1 KDa.
The IGF2 protein is an important member of the insulin-like growth factor family and plays an important role in mammalian growth, fetoplacental development, and adult glucose metabolism. Regulated by placental prolactin, affecting tissue differentiation. IGF2 Protein, Human (P.pastoris) is the recombinant human-derived IGF2 protein, expressed by P. pastoris , with tag free. The total length of IGF2 Protein, Human (P.pastoris) is 67 a.a., with molecular weight of ~7.5 kDa.
IGFBP-5 is only one of a family of six IGFBPs. IGFBP-5 is a 29 kDa phosphorylated and glycosylated protein, which is secreted by a wide variety of cell types during different growth conditions. IGFBP-5, the most conserved IGFBP, is the major protein secreted by skeletal muscles. IGFBP-5 Protein, Canine (HEK293, Fc) is the recombinant canine-derived IGFBP-5 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of IGFBP-5 Protein, Canine (HEK293, Fc) is 252 a.a., with molecular weight of ~40 & 43 & 45 & 65 KDa, respectively.
IGFBP-1 Protein, a member of the insulin-like growth factor-binding protein (IGFBP) family, extends IGFs' half-life and modulates their growth-promoting effects on cell culture, inhibiting or stimulating these responses. Crucially, it alters the interaction between IGFs and their cell surface receptors and promotes cell migration. Notably versatile, IGFBP-1 shows equal binding affinity for both IGF1 and IGF2, underscoring its diverse role in modulating the biological activities of insulin-like growth factors. IGFBP-1 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived IGFBP-1 protein, expressed by HEK293 , with C-His labeled tag. The total length of IGFBP-1 Protein, Rhesus Macaque (HEK293, His) is 234 a.a., with molecular weight of ~30 kDa.
The IGF-I protein is structurally similar to insulin and has excellent growth-promoting activity. As a potential physiological regulator, it affects [1-14C]-2-deoxy-D-glucose (2DG) transport and glycogen synthesis in osteoblasts. Animal-Free IGF-I Protein, Pig (His) is the recombinant pig-derived animal-FreeIGF-I protein, expressed by E. coli , with C-His labeled tag. The total length of Animal-Free IGF-I Protein, Pig (His) is 70 a.a., with molecular weight of ~8.59 kDa.
IGF-I/IGF-1 Protein, part of the insulin family, is highlighted. IGF-I/IGF-1 Protein, Mouse (P.pastoris) is the recombinant mouse-derived IGF-I/IGF-1 protein, expressed by P. pastoris, with tag free. The total length of IGF-I/IGF-1 Protein, Mouse (P.pastoris) is 70 a.a., with molecular weight of ~7.7 kDa.
IGFBP-1 Protein is a member of the insulin-like growth factor binding protein (IGFBP) family that binds insulin-like growth factor (IGFs) I and II to extend the half-life of IGFs. IGFBP-1 inhibits proliferation, invasion, migration and apoptosis of HTR-8/SVneo cells by inducing MMP-26 expression. IGFBP1 may be a new prognostic factor and a target of molecular targeted therapy for gastric cancer. IGFBP-1 Protein, Canine (HEK293, His) is the recombinant canine-derived IGFBP-1 protein, expressed by HEK293 , with C-His labeled tag. The total length of IGFBP-1 Protein, Canine (HEK293, His) is 224 a.a., with molecular weight of ~27 kDa.
The LR3 IGF-I/IGF-1 protein is similar to insulin and has potent growth-promoting activity that exceeds the efficacy of insulin. As a potential physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts even at significantly lower concentrations than insulin. IGF-I/IGF-1 Protein, Human (HEK293, hFc) is the recombinant human-derived IGF-I/IGF-1 protein, expressed by HEK293 , with N-hFc labeled tag. The total length of IGF-I/IGF-1 Protein, Human (HEK293, hFc) is 70 a.a., with molecular weight of 35-40 kDa.
The IGFBP-5 protein regulates insulin-like growth factor (IGF) and extends its lifespan. It can inhibit or stimulate the growth-promoting effect of IGF, showing its dual regulatory function. IGFBP-5 Protein, Human (sf9, His) is the recombinant human-derived IGFBP-5 protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of IGFBP-5 Protein, Human (sf9, His) is 252 a.a., with molecular weight of ~30 kDa.
IGFBP-6 protein is an important IGFBP member that regulates insulin-like growth factor (IGF) by changing its interaction with cell surface receptors, thereby affecting IGF-induced growth responses. In addition to regulating IGF signaling, IGFBP-6 also activates the MAPK pathway and induces cell migration. IGFBP-6 Protein, Human (HEK293, His) is the recombinant human-derived IGFBP-6 protein, expressed by HEK293 , with C-His labeled tag. The total length of IGFBP-6 Protein, Human (HEK293, His) is 240 a.a., with molecular weight of ~36 kDa.
IGFBP-7 Protein, with relatively low IGF-I and IGF-II affinity, stimulates prostacyclin (PGI2) production and enhances cell adhesion. The significance of its interaction with VPS24/CHMP3 remains uncertain and warrants further investigation. IGFBP-7 Protein, Human (HEK293, Fc) is the recombinant human-derived IGFBP-7 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of IGFBP-7 Protein, Human (HEK293, Fc) is 256 a.a., with molecular weight of 60-70 kDa.
IGFBP-6 protein modulates IGFs' activity, extending their half-life and exhibiting dual regulatory capacity. It activates the MAPK pathway, induces cell migration, and interacts with PHB2. These diverse functions emphasize IGFBP-6's multifaceted role in cellular responses related to growth regulation, signaling, and migration. IGFBP-6 Protein, Rat (HEK293, His) is the recombinant rat-derived IGFBP-6 protein, expressed by HEK293 , with C-His labeled tag. The total length of IGFBP-6 Protein, Rat (HEK293, His) is 201 a.a., with molecular weight of 25-30 kDa.
IGFBP-5 protein modulates IGFs, extending their life span and regulating their growth effects. It inhibits or stimulates IGFs, showing its dual function. By altering IGFs' interaction with cell receptors, IGFBP-5 fine-tunes growth-associated signaling pathways, governing cellular responses. This interplay reveals IGFBP-5's multifaceted role in cellular growth and proliferation. IGFBP-5 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived IGFBP-5 protein, expressed by HEK293 , with C-His labeled tag. The total length of IGFBP-5 Protein, Cynomolgus (HEK293, His) is 252 a.a., with molecular weight of ~35 kDa.
IGFBP-3 protein is a part of IGFBP that significantly prolongs IGF half-life and modulates growth effects in cell culture. It inhibits or stimulates IGF-induced cellular responses by changing the kinetics of interaction with cell surface receptors. IGFBP-3 Protein, Human (HEK293, His) is the recombinant human-derived IGFBP-3 protein, expressed by HEK293 , with N-His labeled tag. The total length of IGFBP-3 Protein, Human (HEK293, His) is 264 a.a., with molecular weight of 40-45 kDa.
IGFBP-7 Protein is a member of the insulin-like growth factor binding protein (IGFBP) Family. The major function of IGFBP-7 is the regulation of availability of insulin-like growth factors (IGFs) in tissue as well as in modulating IGF binding to its receptors. IGFBP7 exhibits a relatively low affinity for binding to both IGF-I and IGF-II. Furthermore, it has the capacity to stimulate the production of prostacyclin (PGI2) and enhance cell adhesion. IGFBP-7 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived IGFBP-7 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of IGFBP-7 Protein, Mouse (HEK293, Fc) is 256 a.a., with molecular weight of ~53.3-60 kDa.
IGFBP-4 protein modulates IGFs' activity and can either inhibit or stimulate their growth-promoting effects. It alters the interaction between IGFs and their receptors, with a preference for binding to IGF2. This highlights the nuanced role of IGFBP-4 in fine-tuning IGF-mediated cellular responses. IGFBP-4 Protein, Mouse (HEK293, His) is the recombinant mouse-derived IGFBP-4 protein, expressed by HEK293 , with C-His labeled tag. The total length of IGFBP-4 Protein, Mouse (HEK293, His) is 254 a.a., with molecular weight of ~38 kDa.
IGFBP-2 protein, a member of the IGF-binding protein family, inhibits IGF-mediated growth and developmental rates. It can extend the half-life of IGF and exhibit dual functions by inhibiting or stimulating the growth-promoting effect of IGF in cell culture. IGFBP-2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived IGFBP-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of IGFBP-2 Protein, Mouse (HEK293, His) is 271 a.a., with molecular weight of ~32-40 kDa.
IGFBP-2 protein, a member of the IGF-binding protein family, inhibits IGF-mediated growth and developmental rates. It can extend the half-life of IGF and exhibit dual functions by inhibiting or stimulating the growth-promoting effect of IGF in cell culture. IGFBP-2 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived IGFBP-2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of IGFBP-2 Protein, Mouse (HEK293, Fc) is 305 a.a., with molecular weight of ~56.6 kDa.
IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (HEK293, His) is the recombinant human-derived IGF-I R protein, expressed by HEK293 , with C-6*His labeled tag. The total length of IGF-I R Protein, Human (HEK293, His) is 902 a.a., with molecular weight of 100-130 & 54 kDa, respectively.
IGFBP-6 protein can extend the half-life of IGF and regulate its effects. It can inhibit or stimulate the growth-promoting effects of IGF. IGFBP-6 Protein, Mouse (HEK293, His) is the recombinant mouse-derived IGFBP-6 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of IGFBP-6 Protein, Mouse (HEK293, His) is 213 a.a., with molecular weight of ~28.0 kDa.
IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (sf9, His-GST) is the recombinant human-derived IGF-I R protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of IGF-I R Protein, Human (sf9, His-GST) is 414 a.a., with molecular weight of ~74.6 kDa.
IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (HEK293, His, solution) is the recombinant human-derived IGF-I R protein, expressed by HEK293 , with C-His labeled tag. The total length of IGF-I R Protein, Human (HEK293, His, solution) is 902 a.a., with molecular weight of ~150 kDa.
IGFBP-4 protein lacks essential conserved residue(s) for propagating feature annotation. IGFBP-4 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived IGFBP-4 protein, expressed by HEK293 , with C-His labeled tag. The total length of IGFBP-4 Protein, Cynomolgus (HEK293, His) is 235 a.a., with molecular weight of 33-36 kDa.
The LR3 IGF-I/IGF-1 protein is similar to insulin and has potent growth-promoting activity that exceeds the efficacy of insulin. As a potential physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts even at significantly lower concentrations than insulin. IGF-I/IGF-1 Protein, Human (67a.a) is the recombinant human-derived IGF-I/IGF-1 protein, expressed by E. coli , with tag free. The total length of IGF-I/IGF-1 Protein, Human (67a.a) is 67 a.a., with molecular weight of ~9.0 kDa.
The LR3 IGF-I/IGF-1 protein is similar to insulin and has potent growth-promoting activity that exceeds the efficacy of insulin. As a potential physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts even at significantly lower concentrations than insulin. IGF-I/IGF-1 Protein, Human (G49-A118) is the recombinant human-derived IGF-I/IGF-1 protein, expressed by E. coli , with tag free. The total length of IGF-I/IGF-1 Protein, Human (G49-A118) is 70 a.a., with molecular weight of ~9.0 kDa.
The IGFBP-1 protein is an insulin-like growth factor binding protein that extends the half-life of IGF and modulates its growth-promoting effects in cell cultures, thereby inhibiting or stimulating these responses. Crucially, it alters the interaction between IGF and its cell surface receptors and promotes cell migration. IGFBP-1 Protein, Mouse (SUMO, His) is the recombinant mouse-derived IGFBP-1 protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag. The total length of IGFBP-1 Protein, Mouse (SUMO, His) is 247 a.a., with molecular weight of ~43 kDa.
The LR3 IGF-I/IGF-1 protein is similar to insulin and has potent growth-promoting activity that exceeds the efficacy of insulin. As a potential physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts even at significantly lower concentrations than insulin. IGF-I/IGF-1 Protein, Human (P. pastoris, N-His) is the recombinant human-derived IGF-I/IGF-1 protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of IGF-I/IGF-1 Protein, Human (P. pastoris, N-His) is 70 a.a., with molecular weight of 9.7 kDa.
IGFBP-1 protein extends the half-life of IGFs and modulates their activity. It can inhibit or stimulate IGFs' growth-promoting effects, altering their interaction with receptors and fine-tuning signaling pathways. IGFBP-1 promotes cell migration and binds to both IGF1 and IGF2, highlighting its versatile role in modulating IGF signaling pathways. IGFBP-1 Protein, Human (HEK293, His) is the recombinant human-derived IGFBP-1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of IGFBP-1 Protein, Human (HEK293, His) is 234 a.a., with molecular weight of 30-35 kDa.
The LR3 IGF-I/IGF-1 protein is similar to insulin and has potent growth-promoting activity that exceeds the efficacy of insulin. As a potential physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts even at significantly lower concentrations than insulin. LR3 IGF-I/IGF-1 Protein, Human (83a.a, E51R) is the recombinant human-derived LR3 IGF-I/IGF-1 protein, expressed by E. coli , with tag free. and E51R, , , , mutation. The total length of LR3 IGF-I/IGF-1 Protein, Human (83a.a, E51R) is 70 a.a., with molecular weight of ~11.0 kDa.
IGFBP‐2 is a member of a family of six insulin‐like growth factor (IGF) binding proteins. IGFBP-2 is the second most abundant IGFBP in the circulation and binds IGF-II with higher affinity than IGF-I. IGFBP-2 has been implicated in the regulation of IGF activity in most tissues and organs. IGFBP-2 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived IGFBP-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of IGFBP-2 Protein, Rhesus Macaque (HEK293, His) is 289 a.a., with molecular weight of ~33 KDa.
IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (His) is the recombinant human-derived IGF-I R protein, expressed by E. coli , with N-6*His labeled tag. The total length of IGF-I R Protein, Human (His) is 169 a.a., with molecular weight of ~23.4 kDa.
The LR3 IGF-I/IGF-1 protein is similar to insulin and has potent growth-promoting activity that exceeds the efficacy of insulin. As a potential physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts even at significantly lower concentrations than insulin. GMP LR3 IGF-I/IGF-1 Protein, Human (83a.a, E51R) is the recombinant human-derived LR3 IGF-I/IGF-1 protein, expressed by E. coli , with tag free. The total length of GMP LR3 IGF-I/IGF-1 Protein, Human (83a.a, E51R) is 70 a.a., with molecular weight of ~11 kDa.
The LR3 IGF-I/IGF-1 protein is similar to insulin and has potent growth-promoting activity that exceeds the efficacy of insulin. As a potential physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts even at significantly lower concentrations than insulin. Animal-Free IGF-I/IGF-1 Protein, Human (His) is the recombinant human-derived animal-FreeIGF-I/IGF-1 protein, expressed by E. coli , with C-His labeled tag. The total length of Animal-Free IGF-I/IGF-1 Protein, Human (His) is 70 a.a., with molecular weight of ~8.59 kDa.
IGFBP-4 protein is an important IGFBP member that prolongs the half-life of insulin-like growth factor (IGF) and modulates its effects on cell cultures by altering the kinetics of interaction with cell surface receptors. It can inhibit or stimulate IGF-induced growth responses, showing specificity for IGF2 but not IGF1. IGFBP-4 Protein, Human (237a.a, HEK293, His) is the recombinant human-derived IGFBP-4 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of IGFBP-4 Protein, Human (237a.a, HEK293, His) is 237 a.a., with molecular weight of 30-35 kDa.
The IGF2BP2 protein is an RNA-binding factor that coordinates the recruitment of target transcripts into cytoplasmic mRNP, promoting mRNA transport and transient storage. It regulates the contact of target transcripts with the translation machinery and protects them from microRNA-mediated degradation. IGF2BP2 Protein, Human (sf9, His-GST) is the recombinant human-derived IGF2BP2 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of IGF2BP2 Protein, Human (sf9, His-GST) is 599 a.a., with molecular weight of ~90 kDa.
The IGFBP-1 protein is an insulin-like growth factor binding protein that extends the half-life of IGF and modulates its growth-promoting effects in cell cultures, thereby inhibiting or stimulating these responses. Crucially, it alters the interaction between IGF and its cell surface receptors and promotes cell migration. IGFBP-1 Protein, Mouse (P. pastoris, N-His) is the recombinant mouse-derived IGFBP-1 protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of IGFBP-1 Protein, Mouse (P. pastoris, N-His) is 247 a.a., with molecular weight of 44 kDa.
The IGFBP-5 protein regulates insulin-like growth factor (IGF) and extends its lifespan. It can inhibit or stimulate the growth-promoting effect of IGF, showing its dual regulatory function. IGFBP-5 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived IGFBP-5 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of IGFBP-5 Protein, Human (Biotinylated, HEK293, His-Avi) is 252 a.a., with molecular weight of 32-45 kDa.
IGFBP-7 Protein, with relatively low IGF-I and IGF-II affinity, stimulates prostacyclin (PGI2) production and enhances cell adhesion. The significance of its interaction with VPS24/CHMP3 remains uncertain and warrants further investigation. IGFBP-7 Protein, Human (HEK293, His) is the recombinant human-derived IGFBP-7 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of IGFBP-7 Protein, Human (HEK293, His) is 256 a.a., with molecular weight of 30-35 kDa.
IGFBP-7 Protein, with modest affinity, binds to IGF-I and IGF-II, and notably stimulates prostacyclin (PGI2) production. Beyond its interaction with insulin-like growth factors, IGFBP-7 contributes to cell adhesion, indicating its role in cellular processes associated with adhesion and potential influence on cell-matrix interactions. These functionalities highlight IGFBP-7's diverse roles in modulating growth factor signaling and cellular responses. IGFBP-7 Protein, Mouse (HEK293, His) is the recombinant mouse-derived IGFBP-7 protein, expressed by HEK293, with C-His labeled tag. The total length of IGFBP-7 Protein, Mouse (HEK293, His) is 256 a.a., with molecular weight of 32-38 kDa.
IGFBP-5 protein is a member of the IGFBP family that significantly prolongs the half-life of IGF and modulates its growth-promoting effects in cell culture. The multifunctional IGFBP-5 can inhibit or stimulate cellular responses to IGF by altering the kinetics of interaction with IGF receptors. IGFBP-5 Protein, Mouse (HEK293, His) is the recombinant mouse-derived IGFBP-5 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of IGFBP-5 Protein, Mouse (HEK293, His) is 252 a.a., with molecular weight of ~38.0 kDa.
Connective tissue growth factor; CCN family member 2; Hypertrophic chondrocyte-specific protein 24; insulin-like growth factor-binding protein 8; CTGF; IGFBP8
CCN2/CTGF (Connective Tissue Growth Factor) is a protein produced primarily by endothelial cells in blood vessels. It plays an important role in various cellular processes. CCN2/CTGF Protein, Human (HEK293, Fc) is the recombinant human-derived CCN2/CTGF protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CCN2/CTGF Protein, Human (HEK293, Fc) is 323 a.a., with molecular weight of ~115.37 kDa (Non-reducing) and 63.5 & 35 kDa (Reducing), respectively.
rHuCCN family member 1/Cyr61, Fc; Protein CYR61; CCN family member 1; Cysteine-rich angiogenic inducer 61; insulin-like growth factor-binding protein 10 ; GIG1; CYR61; CCN1; IGFBP10;
CCN1/Cyr61 proteins play critical roles in cellular processes, promoting cell proliferation, chemotaxis, angiogenesis, and adhesion. It coordinates wound healing by upregulating key genes related to angiogenesis, inflammation and matrix remodeling in skin fibroblasts and is heparin binding dependent. CCN1/Cyr61 Protein, Human (HEK293, Fc) is the recombinant human-derived CCN1/Cyr61 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CCN1/Cyr61 Protein, Human (HEK293, Fc) is 357 a.a., with molecular weight of 71-80 kDa.
CCN2/CTGF (Connective Tissue Growth Factor) is a protein produced primarily by endothelial cells in blood vessels. It plays an important role in various cellular processes. CCN2/CTGF Protein, Human (HEK293) is the recombinant human-derived CCN2/CTGF protein, expressed by HEK293 , with tag free. The total length of CCN2/CTGF Protein, Human (HEK293) is 154 a.a., with molecular weight of ~21.15 kDa.
The IGF2BP2 protein is an RNA-binding factor that coordinates the recruitment of target transcripts into cytoplasmic mRNP, promoting mRNA transport and transient storage. It regulates the contact of target transcripts with the translation machinery and protects them from microRNA-mediated degradation. IGF2BP2 Protein, Human (T7-His) is the recombinant human-derived IGF2BP2 protein, expressed by E. coli , with N-T7, C-6*His labeled tag. The total length of IGF2BP2 Protein, Human (T7-His) is 220 a.a., with molecular weight of ~43.0 kDa.
Picropodophyllin-d6 (AXL1717-d6) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
IGF1R; insulin-like growth factor 1 receptor; insulin-like growth factor I receptor; IGF-I receptor; CD antigen CD221
WB, IHC-P
Human
IGF1 Receptor Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 155 kDa, targeting to IGF1 Receptor. It can be used for WB,IHC-P assays with tag free, in the background of Human.
IGF1R; insulin-like growth factor 1 receptor; insulin-like growth factor I receptor; IGF-I receptor; CD antigen CD221
WB, IP
Human, Mouse, Rat
Phospho-IGF1 Receptor (Tyr1166) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 155 kDa, targeting to Phospho-IGF1 Receptor (Tyr1166). It can be used for WB,IP assays with tag free, in the background of Human, Mouse, Rat.
CTGF Antibody is an unconjugated, approximately 36 kDa, rabbit-derived, anti-CTGF polyclonal antibody. CTGF Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, and predicted: chicken, dog, pig, cow background without labeling.
Human, Mouse, Rat, Dog(predicted: Pig, Cow, Rabbit, Sheep)
IGF 1 Antibody is an unconjugated, approximately 7.7/21 kDa, rabbit-derived, anti-IGF 1 polyclonal antibody. IGF 1 Antibody can be used for: WB, ELISA, IP, IHC-P, IHC-F, IF expriments in human, mouse, rat, dog, and predicted: pig, cow, rabbit, sheep background without labeling.
Cancer/testis antigen 98; CT98; DKFZp686F1078; hKOC; IF2B3_HUMAN; IGF II mRNA binding protein 3; IGF-II mRNA-binding protein 3; IGF2 mRNA binding protein 3; IGF2 mRNA-binding protein 3; IGF2BP3; IMP 3; IMP-3; insulinlike growth factor 2 mRNA binding prot
WB, ICC/IF, IP, FC
Human, Mouse, Rat
IMP3 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 64 kDa, targeting to IMP3. It can be used for WB,ICC/IF,IP,FC assays with tag free, in the background of Human, Mouse, Rat.
Inquiry Online
Your information is safe with us. * Required Fields.
